Gapping up
In reaction to strong earnings/guidance:
- SGH +10.8%, HOME +8.1%, NKE +4.3%, (also has acquired consumer data analytics firm Zodiac), KBH +3.8%, CTAS +1.7%
M&A news:
- GSK +5.8% (GlaxoSmithKline plc (GSK) withdraws from process relating to Pfizer's Consumer Healthcare business)
Other news:
- PACB +10.3% (prevails in patent eligibility ruling against Oxford Nanopore; trial is scheduled to occur in early 2020)
- VTVT +4% (completes Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in type 1 diabetes)
- WYNN +3.5% (announces issuance and sale of 5.3 mln shares of common stock; Stephen Wynn's sale of 8.0 mln shares of common stock)
- LFIN +0.8% (after closing at highs -- up 11% on the day)
Analyst comments:
- CCL +1.4% (upgraded to Overweight from Equal Weight at Barclays)
- DXCM +1.0% (upgraded to Outperform from Neutral at Robert W. Baird)
- DM +1.0% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- GIS +1.0% (upgraded to Positive from Neutral at Susquehanna)
![]()